Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.36 |
| ▸ | FEN1 | P39748 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322395 | 0.94 | SCN9A (0.44) | SCN9ASCN5ASCN10AAOC3PTGER1 | |
| SCHEMBL13754838 | 0.92 | SCN9A (0.47) | SCN9ASCN5AAOC3PTGER1CYP3A4 | |
| SCHEMBL4324603 | 0.90 | SCN9A (0.45) | SCN9ASCN5ASCN10AAOC3CYP3A4 | |
| SCHEMBL4321718 | 0.87 | SCN9A (0.54) | SCN9ASCN5ASCN10AAOC3CYP3A4 | |
| SCHEMBL4331646 | 0.86 | PDE10A (0.45) | SCN9AAOC3PTGER1 | |
| SCHEMBL13913168 | 0.86 | PTGER1 (0.41) | SCN9ASCN5ASCN10APTGER1ALOX5AP | |
| SCHEMBL4321404 | 0.86 | SCN9A (0.48) | SCN9ASCN5ASCN10AAOC3PTGER1 | |
| SCHEMBL4314279 | 0.85 | SCN9A (0.43) | SCN9AAOC3PTGER1 | |
| SCHEMBL4491094 | 0.85 | SCN9A (0.59) | SCN9ASCN10AAOC3CYP3A4CYP2D6 | |
| SCHEMBL4314077 | 0.84 | AOC3 (0.44) | SCN9AAOC3PTGER1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1694654-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | Merck & Co., Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005047270-A2 | SUBSTITUTED TRIAZOLES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885SCN5A 3/4885SCN10A 52/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | SCN9A 50/4885SCN5A 3/4885SCN10A 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.